Skip to search formSkip to main contentSkip to account menu

Poractant alfa 80 MG/ML Intratracheal Suspension [Curosurf]

Known as: Curosurf 80 MG/ML Intratracheal Suspension, PORACTANT ALFA 80 mg in 1 mL ENDOTRACHEAL SUSPENSION [Curosurf] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ABSTRACT Background: Synthetic surfactants represent a promising alternative to animal-derived preparations in the treatment of… 
2014
2014
.............................................................................................................................. 3… 
2011
2011
The interfacial properties of tracheal aspirate from infants with untreated neonatal respiratory distress syndrome (NRDS), and… 
2008
2008
Aims: Optimal preservation of organ function is crucial in clinical lung transplantation as ischemia/reperfusion-injury (IRI… 
2005
2005
Background. Glucocorticoids have been used successfully in the amelioration of chronic lung disease (CLD). Unfortunately, higher… 
2003
2003
The use of exogenous surfactants has been introduced into the therapy of patients of different ages. Much better results have… 
1998
1998
This paper examines the removal from the airways of Curosurf, a commercial surfactant derived from porcine lungs, administered at… 
1996
1996
Background: We have previously shown that Curosurf®, a natural porcine surfactant, suppressed secretion of tumor necrosis factor…